←
Christian Soschner26,966 posts
Christian Soschner avatar

Christian Soschner

@Soschner

Deep Tech Board Advisor | Capital, Valuation & AI Business Model Change | Host, Beginner’s Mind 🎙️ | Scaling, leadership, investing & books

◷ Joined March 2012▧ 1,595 Photos and videos
Christian Soschner avatar
Christian Soschner@Soschner·Nov 8

“This has been on my mind for weeks.” Most of my sessions start with that sentence. A board meeting in March. A round that has to close. A partner to approach first. The question is clear. The calendar is full. And one good conversation fades by Thursday. Research on patient memory puts a number on it: people forget between 40 and 80 percent of what their doctor tells them as soon as the visit ends. Advice fades the same way. For that reason my sessions run in three steps: Prepare. You write down your goal, why it matters and the questions you want answered. Writing shows the open points before we meet. Session. Sixty minutes on your decision, ending with one step and a date, written as “if this happens, then I do that.” De-brief. Within 24 hours, in writing, with the recording and the transcript. Today I published the handbook behind it: every step, six exercises from my toolbox and the research behind each part. It is free. No email form. The link to the article and the download is in the first comment. What decision has been on your mind for weeks?

Post attachment
Ilya Strebulaev avatar
⟳ Christian Soschner retweeted
Ilya Strebulaev@IlyaStrebulaev·4h

There is about to be one less private unicorn soon, and it is a special one. A good moment to look at the private unicorn landscape before Anthropic’s IPO changes it forever. As of October 1, there were 2,030 privately held unicorns in the world, with a combined post-money valuation of $9.0 trillion. Northern America and Asia account for 81% of them by count and 88% of their value. Europe has 14% of the unicorns and 9% of the value. The reason is a handful of very large companies. Anthropic ($965 billion PMV) and OpenAI ($850 billion) are each valued above all European unicorns put together. The two of them make up 20% of global private unicorn value. If Anthropic’s post-IPO value holds up through the lock-up period, many VC investors will hope that the other $8.0 trillion can be unlocked the same way Anthropic’s roughly $1 trillion is about to be. That would ease the profound illiquidity in the VC world and transform the entire US VC industry. P.S. The chart shows every private unicorn with a known valuation, sized by post-money valuation and grouped by region. We will update it after Anthropic’s IPO.

Post attachment
Christian Soschner avatar
Christian Soschner@Soschner·2h

Nvidia doubled its revenue to $115.8 billion in one year. Its biggest risk does not show up anywhere in the report. Five findings from Q3 fiscal 2027: 1. Growth. Revenue up 103%. The Q4 guide of $130 billion beats the $125.1 billion consensus. 2. Customers. AI clouds, industrial and enterprise customers now bring in 44% of data center revenue, up from 31% a year ago. 3. Product. Vera Rubin brought in close to $20 billion in its first quarter. That is more than all of Nvidia earned in the quarter to October 2023. 4. Cash. Free cash flow doubled in one quarter to $43.8 billion. Supply commitments rose to $390 billion, most of it multi-year memory. Demand is strong when buyers reserve capacity years into the future. That is a sellers' market. 5. Drug development. Isomorphic Labs raised $5 billion, the largest venture round in biotech history, and Nvidia is not among its investors. Money of this size buys compute, and compute needs chips. Eli Lilly bought its own AI factory with 1,016 Nvidia GPUs. The real question is the culture. Jensen Huang built a company that out-innovates every competitor and pulls in the best talent. That culture is the moat, even at this scale. Apple had years: Steve Jobs prepared Tim Cook to keep Apple's culture alive. Nvidia has to make that move now. The numbers are strong. They are the look in the rearview mirror. All five charts in the full article: cslifescienceinvest.com/arti…

Post attachment
Christian Soschner avatar
Christian Soschner@Soschner·4h

"“It’s very symbolic,” said Taylor Ogan, founder of Shenzhen-based hedge fund Snow Bull Capital. “China is going to show the world a China that is leading in most technological aspects.” In picking a city that is often likened to Silicon Valley, Xi is telegraphing China’s manufacturing strength as well as its determination to best the U.S. in everything from AI to drones. Shenzhen boasts more billionaires than any other global city except New York, according to the Hurun Rich List." China and Xi are not playing for the sake of being in the game. They are in it to win it. In every single industry. Europe, which industry do we pick to lead? The regulation industry? wsj.com/world/china/in-choos…

Post attachment
Christian Soschner avatar
Christian Soschner@Soschner·6h

To read

a16z@a16zNov 17

On Friday, January 27, 2017, Elon Musk asked the SpaceX team how long it would take to clear the employee parking lot across the street and start digging. The team said two weeks. "Why two weeks?" Musk asked. "Let's get started today and see what's the biggest hole we can dig between now and Sunday afternoon, running 24 hours a day." Within three hours, the cars in the parking lot were moved and there was a hole in the ground. Musk wanted it visible from his office so he could see that it was being built, and put Steve Davis in charge. a16z's David George, Jamie Sullivan, and Michael McGuiness on The Boring Company & the Future Underground: a16z.news/p/the-boring-compa…

Post attachment
Christian Soschner avatar
Christian Soschner@Soschner·Nov 17

Demis Hassabis: $5 billion to “Solve All Disease.” Dario Amodei: AI cures most diseases within 5 to 10 years. Of every 100 drugs entering human trials, about 8 reach approval, after 10.5 years. What has to happen by 2036 for both to be right: cslifescienceinvest.com/deep…

Christian Soschner avatar
Christian Soschner@Soschner·Nov 17

amazing

Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...

0:37
Christian Soschner avatar
Christian Soschner@Soschner·Nov 17

Clear anti-handoverism. Design tools to help humans become better.

It is critically important that everyone thinking about AI become familiar with the term “handoverism.” Many in the AI community believe that humanity should—or inevitably will—hand control of the world over to AI itself. Some view this not as a risk to be avoided, but as an outcome to be welcomed. Are we actually designing toward this future? This worldview is particularly relevant at Anthropic. Co-founder Tom Brown said: “There’s going to be a handoff where humanity will hand off control to transformative AI at some point.” In his seminal essay, Machines of Loving Grace, CEO Dario Amodei contemplates: “It could be a capitalist economy of AI systems, which then give out resources (huge amounts of them, since the overall economic pie will be gigantic) to humans based on some secondary economy of what the AI systems think makes sense to reward in humans (based on some judgment ultimately derived from human values).” Are you prepared to receive your “resources” from an AI system, based on criteria it determines? The full title of the poem Dario borrowed the title from is "All Watched Over by Machines of Loving Grace." Do you want to be "watched over" by AI? If Anthropic's founders believe that the ultimate destination is the transfer of human control to AI, the world deserves to know. Washington, D.C. deserves to know. American citizens deserve to know. And if that belief informs Anthropic's corporate objectives, it belongs in the Risk Factors section of its S-1. It isn't there today. I am decidedly anti-handoverism. I'm not here to tell you what your view should be. But I believe anyone making consequential decisions about AI—especially those drafting, advocating for, or enacting AI regulation—should be required to disclose where they stand on this fundamental question. A wonderfully thoughtful piece on the subject by @RuxandraTeslo: writingruxandrabio.com/p/han…

Christian Soschner avatar
Christian Soschner@Soschner·Nov 17

Check this out

"Lilly made 64% of its 2025 sales from medicines approved in the last five years. Sanofi is second, at 14%. Amgen is third, at 12%. Everyone else in the top 20 is in single figures, and Gilead and Novo Nordisk are at zero. The revenue age tells the same story, even if it does it more quietly. Lilly’s is 6.6 years. For most of the group, it sits between eleven and thirteen." @DaveARicks The Aftermath Index asymmetriclearning.substack.…

Post attachmentPost attachment
Christian Soschner avatar
Christian Soschner@Soschner·Nov 17

Worth reading

As a teenager, Elon Musk went through an existential crisis, reading religion and philosophy in search of the meaning of life Then he discovered Douglas Adams' The Hitchhiker's Guide to the Galaxy “I ended up reading The Hitchhiker's Guide to the Galaxy, which is actually a book on philosophy, just sort of disguised as a silly humor book. But it's actually a philosophy book. And Adams makes the point that it's actually the question that is harder than the answer” A seemingly silly humor book helped a teenager searching for meaning realize something profound Finding the right question is often harder than finding the answer And that curiosity never left him Today, it's driving him to build rockets, explore the universe, and push humanity toward the stars

Post attachment
Christian Soschner avatar
Christian Soschner@Soschner·Nov 17

Read this

Zina Sarif @zinasarif Nov 16 Article Beyond Biology: Why Are Clinical Trials So Slow? It is 2026, and science is moving faster than the system built to test it. The problem is not only biology or regulation. It is an industry that has learned to manage individual risks without managing

Christian Soschner avatar
Christian Soschner@Soschner·Nov 17

Worth reading

Healthcare is now AI’s biggest vertical market. Spend grew 2.5x to $3.7B this year, more than double legal ($1.8B) and more than legal and finance combined. It started in paperwork: scribing and billing. Now it’s moving into drug discovery, patient engagement and clinical decision support. Clinical copilots alone grew 5.5x to $550M. Our 2026 State of AI in Healthcare report from @grgyap, @jpsanday, @CroomBeatty, @hu_j, @derekgxiao and @sabrinarlu: mnlo.vc/2026-healthcare-ai-r…